Symptomatic progestin-associated atypical grade II meningioma. A first case report - 19/06/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Long-term use of high doses of prgestin promotes the development of meningiomas. |
• | Physicians should be aware of the possible aggressiveness of meningioma in patients under progestin. |
• | There is a higher risk for patients treated by multiple progestin over a long period of time without interruption. |
• | These patients require a systematic, close monitoring, and possibly require specific neurosurgical management. |
Abstract |
Background |
Long-term use of high-dose progestin is known to promote the development of meningioma. Atypical meningioma in a patient under progestin has not previously been reported.
Case report |
A 53-year-old right-handed woman presented with focal onset seizures, without impaired consciousness. Medical history featured endometriosis, treated successively by cyproterone acetate 25mg/day for 2 months then 50mg/day for 101 months, and chlormadinone acetate 5mg/day for 68 months then 10mg/day for 83 months. Brain MRI revealed multiple extra-axial lesions suggestive of left central meningioma associated with anterior skull base meningiomatosis. Surgical resection of the left central meningioma was achieved and progestin was withdrawn. Neuropathology diagnosed grade II atypical meningioma. Close clinical and imaging monitoring was implemented without adjuvant oncological treatment. At 25 months, imaging follow-up showed no recurrence of the left central meningioma and a significant regression of all other lesions, except for the right frontal lesion.
Conclusions |
Neurosurgeons should be aware of the possible aggressiveness of meningioma in patients under progestin, and particularly those treated by different types of progestin over a long period of time without interruption. This may require systematic close monitoring, to adapt neurosurgical management.
Le texte complet de cet article est disponible en PDF.Keywords : Atypical meningioma, Chlormadinone acetate, Cyproterone acetate, Neurosurgery, Progesterone agonist
Plan
Vol 66 - N° 3
P. 174-178 - juin 2020 Retour au numéro
Article précédent
- Temporal and spatial expression of Sox9, Pax1, TGF-β1 and type I and II collagen in human intervertebral disc development
- G. Xu, Y. Liu, C. Zhang, Y. Zhou, S. Hou, J. Tang, Z. Li
- Case report: Mini-invasive surgery assisted by Da Vinci® robot for a recurrent paravertebral schwannoma
- L. Matveeff, J.M. Baste, V. Gilard, S. Derrey
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?